C. P. M. Ronteltap - Concepedia

Author

C. P. M. Ronteltap

Rotterdam University of Applied Sciences

Also Known As

C P M Ronteltap, C P Ronteltap, C Ronteltap, C. P. M. Ronteltap, C. RONTELTAP, C.P.M. Ronteltap, Cees P. Ronteltap, Cees Ronteltap

Publications

723

Citations

H-Index

Concepts

All Affiliations

Rotterdam University of Applied Sciences Hydrobiological Institute Erasmus University Rotterdam Netherlands Organisation for Applied Scientific Research Erasmus MC Cancer Institute

About

C. P. M. Ronteltap is an author at Rotterdam University of Applied Sciences specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	480
2	Cell Biology	8	8	455
3	Health Sciences	1	1	80
4	Blood Transplantation	1	1	12
5	Cellular Physiology	1	1	10

C. P. M. Ronteltap

Publications

710

Citations

H-Index

Page 1

	Year	Citations
Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR Ralph A. Willemsen, M. E. M. Weijtens, C. P. M. Ronteltap, Gene Therapy Cell TherapyCancer ImmunosurveillanceImmunologyPrimary Human TChain Tcr	2000	169
Characterization of natural killer (NK) cells and killer (K) cells in human blood: Discrimination between NK and K cell activities R. L. H. Bolhuis, H. R. E. Schuit, A. M. Nooyen, European Journal of Immunology ImmunohematologyLaboratory ImmunologyLymphocyte DevelopmentImmunologyImmune Regulation	1978	80
Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells. R J van de Griend, B.A. Van Krimpen, C. P. M. Ronteltap, The Journal of Immunology T-regulatory CellNull CellsImmunologyPathologyImmunologic Mechanism	1984	71
T Cell Retargeting with MHC Class I-Restricted Antibodies: The CD28 Costimulatory Domain Enhances Antigen-Specific Cytotoxicity and Cytokine Production Ralph A. Willemsen, C. P. M. Ronteltap, Patrick Chames, The Journal of Immunology	2005	68
Lysis of tumor cells by CD3+4-8-16+ T cell receptor <i>alpha</i> <i>beta</i>- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon <i>beta</i>. R J van de Griend, W.J.M. Tax, B.A. Van Krimpen, The Journal of Immunology	1987	68
Optimization of culture conditions for activation and large‐scale expansion of human T lymphocytes for bispecific antibody‐directed cellular immunotherapy C. B. H. W. Lamers, R J van de Griend, Eric Braakman, International Journal of Cancer	1992	57
Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α Rob Willemsen, C. P. M. Ronteltap, M Heuveling, Gene Therapy Cancer ImmunosurveillanceHuman Cd4+ TAdaptive Immune SystemImmunologyTumor Immunity	2004	44
Interferon-<i>beta</i> and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones. R J van de Griend, C. P. M. Ronteltap, Claudia Gravekamp, The Journal of Immunology	1986	37
Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. C J Blank-Voorthuis, E Braakman, C. P. M. Ronteltap, The Journal of Immunology ImmunologyImmunologic MechanismBsmab-pretargeted CtlClustered Cd3/tcr ComplexesImmunotherapy	1993	31
CD8α Coreceptor to Improve TCR Gene Transfer to Treat Melanoma: Down-Regulation of Tumor-Specific Production of IL-4, IL-5, and IL-10 Ralph A. Willemsen, Zsolt Sebestyén, C. P. M. Ronteltap, The Journal of Immunology T-regulatory CellImmune RegulationImmunologyImmunoeditingImmunologic Mechanism	2006	26

Page 1